

FANCONI CANADA

Financial Statements

December 31st, 2014

Prepared By:

Annette Waxberg
Treasurer

June 30, 2015

FANCONI CANADA**Statement of Financial Position**

As at December 31, 2014

	<u>Dec. 31, 2014</u>	<u>Dec. 31, 2013</u>
CURRENT ASSETS		
Bank accounts	\$307,432	\$59,503
GIC and other current assets	153,436	333,957
TOTAL CURRENT ASSETS	<u>\$460,868</u>	<u>\$393,460</u>
LIABILITIES & NET ASSETS		
Payables	\$632	\$35
Net assets internally restricted for research (note 3)	422,084	349,179
Unrestricted net assets	38,152	44,246
TOTAL LIABILITIES & NET ASSETS	<u>\$460,868</u>	<u>\$393,460</u>

June 30, 2015

FANCONI CANADA**Statement of Operations**

For the year ended December 31, 2014

	<u>Jan. 1, 2014 to Dec. 31, 2014</u>	<u>Jan. 1, 2013 to Dec. 31, 2013</u>
REVENUES		
Research contributions	\$166,685	\$176,605
Interest income and rebates	1,945	4,003
Total revenues	<u>\$168,630</u>	<u>\$180,608</u>
GRANTS & EXPENSES		
Research projects funded (notes 4 to 10)	51,467	\$107,925
Direct Fundraising expenses	42,313	40,836
Administrative expenses	8,039	3,076
Total grants & expenses	<u>\$101,819</u>	<u>\$151,837</u>
Excess <deficit> of revenues over grants & expenses	<u>\$66,811</u>	<u>28,771</u>

June 30, 2015

FANCONI CANADA**Statement of Changes in Net Assets**

As at Dec. 31, 2014

	<u>Internally Restricted for Research</u>	<u>Unrestricted</u>	<u>Dec. 31, 2014</u>	<u>Dec. 31, 2013</u>
NET ASSETS				
Balance, beginning of year	\$349,179	\$44,246	\$393,425	\$364,654
Excess <deficit> of revenues over expenses, research	72,905		72,905	27,844
Excess <deficit> of expenses over revenues, administration		<6,094>	<6,094>	927
BALANCE, END OF YEAR	<u>\$422,084</u>	<u>38,152</u>	<u>460,236</u>	<u>\$393,425</u>

June 30, 2015

FANCONI CANADA**Statement of Cash Flows**

For the year ended December 31, 2014

	<u>Jan. 1, 2014 to Dec. 31, 2014</u>	<u>Jan. 1, 2013 to Dec. 31, 2013</u>
Cash flows from operating activities		
Net fundraising for research (note 4):		
Ontario Fundraiser	\$81,179	\$99,563
Scotiabank Waterfront Run	19,241	21,394
LAWPRO Employee Fundraising	5,205	4,850
Lauzier Family Fundraiser	13,816	3,565
Kestenberg Siegel Lipkus Casual Days	2,198	2,240
Tribute Cards	338	2,000
General Donations	1,343	712
	<hr/>	<hr/>
	123,320	134,324
Administrative contributions	-	-
Interest and rebates	1,945	4,003
Research projects:		
Larin (note 5)	-	<4,375>
Kwan (note 6)	<1,667>	<22,500>
Chu (note 7)	-	<17,500>
Mateo (note 8)	<12,500>	<16,250>
Carreau (note 9)	-	<47,300>
Lee (note 10)	<35,800>	-
Marrow Failure Conference	<1,500>	-
Administrative costs	<6,987>	<1,630>
Net increase <decrease> in working capital	<315>	<1,330>
Net cash generated through operating activities	<hr/>	<hr/>
	66,496	27,442
Cash flows from financing & investing activities	-	-
Cash & GIC's, beginning of year	392,181	364,739
Cash & GIC's, end of year	<hr/>	<hr/>
	458,677	392,181

FANCONI CANADA**Notes to Financial Statements**

As at December 31, 2014

1. Purpose of the Organization

Fanconi Canada (Canadian Fanconi Anemia Research Fund/La Fondation Canadienne de Recherche de L'Anemie de Fanconi) raises money to fund research on finding a cure and/or treatment for Fanconi Anemia (a fatal genetic disease causing bone marrow failure and physical anomalies); to raise awareness among members of the general public and the medical community about Fanconi Anemia, its diagnosis and methods of treatment; to provide support to Canadian families affected by Fanconi Anemia; and the publication of newsletters and educational materials in furtherance of the foregoing objectives. On October 15, 2014 Fanconi Canada transitioned its incorporation to the Canada Not-for-profit Corporations Act, from the previous Canada Corporations Act. Fanconi Canada is a registered charity under the Income Tax Act.

2. Significant Accounting Policies**Revenue recognition**

Fanconi Canada follows the deferral method of accounting for contributions. Restricted contributions are recognized as revenue in the year in which the related expenses are incurred. Unrestricted contributions are recognized as revenue when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured. Unrestricted investment income is recognized as revenue when earned.

Investments

Investments are recorded at the lower of cost and market value.

Contributed services

Volunteers contribute many hours per year to assist Fanconi Canada in carrying out its service delivery activities, fundraising and day-to-day operations. Because of the difficulty of determining their fair value, contributed services are not recognized in the financial statements.

3. Restrictions on net assets

Fanconi Canada has no net assets with externally imposed restrictions; however, donations from the public are internally restricted to be used for research. Some donations from families afflicted with Fanconi Anemia are directed to cover Fanconi Canada services and administrative expenses, which are also covered by interest revenue.

4. Raffles at Ontario Fundraisers 2013 and 2014

Fanconi Canada ran a raffle for prizes at the 2013 and 2014 Ontario Fundraisers, both of which required a Lottery Licence from the City of Toronto, numbered M721698 and M775739 respectively. The use of lottery proceeds must benefit a Toronto resident according to the licence restrictions. Accordingly, the proceeds from 2013 raffle continued to fund Meghan Larin (see note 5) and also were used to fund Abigail Mateo (see note 11), both carrying out research in Toronto. In 2014 the entire proceeds of the raffle continued to fund Abigail Mateo.

5. Contractual Obligations – Meghan E. Larin

Fanconi Canada in partnership with the Canadian Institutes of Health Research, has agreed to fund (under the 2009 CIHR Small Health Organization Partnership Program), a three-year doctoral research award to Meghan E. Larin of the University of Toronto, Department of Pharmacology and Toxicology for her project entitled *Fanconi Anemia signaling and Mus81-Eme1: role in replicative stress and development*. The Award is for \$22,000 per year for a total of \$66,000 funded equally by Fanconi Canada and CIHR from September 1, 2010 to August 31, 2013.

6. Contractual Obligations – David Howe Kwan

Fanconi Canada in partnership with the Canadian Institutes of Health Research (under the 2010 CIHR Small Health Organization Partnership Program), has granted a three-year Fellowship Award to David Howe Kwan of the University of British Columbia for his project *Improving Enzymatic Removal of Major Blood Antigens* to help improve the availability and safety of blood transfusions. The award is for \$45,000 per year for a total of \$135,000 funded equally by Fanconi Canada and CIHR from May 1, 2011 to April 30, 2014.

7. Contractual Obligations – Dr. Jeffrey S. Chu

Fanconi Canada in partnership with the Canadian Institutes of Health Research (under the 2012 CIHR Small Health Organization Partnership Program), has granted a three-year Fellowship Award to Jeffrey S. Chu of the University of British Columbia for his project *Characterization of genomic alteration in C. elegans lacking Fanconi anemia pathway function* to better understand the FA pathway. The award is for \$45,000 per year for a total of \$135,000 funded equally by Fanconi Canada and CIHR from May 1, 2013 to July 1, 2016. In 2014, a one year leave of absence was approved with a new end date of June 30, 2017. The Fellowship terminated early on March 15, 2015.

8. Contractual Obligations – Abigail Mateo

Fanconi Canada in partnership with the Canadian Institutes of Health Research (under the 2012 CIHR Small Health Organization Partnership Program), has granted a three-year Doctoral Research Award to Abigail Mateo of the Hospital for Sick Children, Toronto for her project *C. elegans p53 family transcription factor has roles in meiotic recombination and DNA interstrand crosslink* to better understand DNA repair with respect to the FA pathway. The award is for \$35,000 per year for a total of \$105,000 funded equally by Fanconi Canada and CIHR from May 1, 2013 to April 30, 2016.

9. Contractual Obligations – Dr. Madeleine Carreau

In 2011, Fanconi Canada in partnership with the Fanconi Anemia Research Fund (FARF) of Eugene Oregon agreed to fund the project *Exploring the role of FANCC in developmental cell death*, carried out by Dr. Madeleine Carreau of Laval University, Quebec City, Quebec. The project was to run from January 1, 2012 to December 31, 2013 requiring \$189,192 in total, to be funded equally by Fanconi Canada and FARF. Subsequently, the project length was shortened by Dr. Carreau to one year with half the amount required for funding. On November 12, 2012 Fanconi Canada agreed to send \$94,596, thereby funding the full amount of the research in two installments, half in 2012 and the other half in 2013.

10. Contractual Obligations – Eva Lee

In 2014, Fanconi Canada funded the project *The role of Fanconi anemia proteins in homologous recombinational repair of DNA double strand breaks in human cells*, in the amount of \$35,800, with Ms. Eva Lee as the principal investigator at the Hospital for Sick Children, for the period November 1, 2014 to October 31, 2015.

June 30, 2015

11. Ontario Fundraiser

The following is a breakdown of the Annual Ontario Fundraiser, the major fundraising initiative for Fanconi Canada.

**Ontario Fundraiser
Amount Raised for Research**

For the year ended December 31, 2014

	<u>2014</u>	<u>2013</u>
REVENUES		
Table sponsorships	\$83,670	\$77,520
Auction items	19,540	29,507
Donations	6,857	16,673
Ticket sales	8,855	9,570
Raffle tickets	5,410	5,890
Event novelties	40	691
Total revenues	<hr/> \$124,372	<hr/> \$137,721
DIRECT FUNDRAISING EXPENSES	<hr/> <42,408 >	<hr/> <41,396>
Amount raised for research	<hr/> \$81,964	<hr/> \$96,325

12. Scotiabank Waterfront Marathon

Fanconi Canada is in the fourth year of entering a team in the Scotiabank Waterfront Marathon as its second most successful fundraising event.

Scotiabank Waterfront Marathon Amount Raised for Research

For the year ended December 31, 2014

	<u>2014</u>	<u>2013</u>
REVENUES		
Team and Individual Runner Sponsorships	\$20,145	\$22,492
DIRECT FUNDRAISING EXPENSES	<u><904></u>	<u><1,098></u>
Amount raised for research	<u>\$19,241</u>	<u>\$21,394</u>